{"commentary":{"count":11,"free_build_floor":8,"listing_floor":3,"by_channel":{"podcast":6,"youtube":5},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04873362\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"Astefania","nct_id":"NCT04873362","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=astefania-nct04873362. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"Astefania","arms":[{"description":"Participants will receive an intravenous (IV) infusion of placebo prior to the IV infusion of trastuzumab emtansine on Day 1 of each 21-day cycle for a total of 14 cycles.","label":"Arm A: Placebo + Trastuzumab Emtansine","type":"ACTIVE_COMPARATOR"},{"description":"Participants will receive an IV infusion of atezolizumab prior to the IV infusion of trastuzumab emtansine on Day 1 of each 21-day cycle for a total of 14 cycles.","label":"Arm B: Atezolizumab + Trastuzumab Emtansine","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2034-10-02","type":"ESTIMATED"},"conditions":["Breast Cancer"],"enrollment":{"count":1188,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Atezolizumab","type":"DRUG"},{"name":"Trastuzumab Emtansine","type":"DRUG"},{"name":"Placebo","type":"DRUG"},{"name":"Trastuzumab","type":"DRUG"}],"last_update":"2026-09-03","lead_sponsor":"Hoffmann-La Roche","official_title":"A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-03-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Invasive Disease-free Survival (IDFS) in the Full Analysis Set (FAS)","timeFrame":"From baseline until the first occurrence of iDFS event or death, through primary analysis data cut off (approximately 7 years)"}],"references":[{"citation":"Hurvitz SA, Bachelot T, Bianchini G, Harbeck N, Loi S, Park YH, Prat A, Gilham L, Boulet T, Gochitashvili N, Monturus E, Lambertini C, Nyawira B, Knott A, Restuccia E, Schmid P. ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer. Future Oncol. 2022 Oct;18(32):3563-3572. doi: 10.2217/fon-2022-0485. Epub 2022 Nov 16.","pmid":"36382554","type":"DERIVED"}],"start_date":{"date":"2021-05-04","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy","url":"https://clinicaltrials.gov/study/NCT04873362"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/astefania-nct04873362"}